Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, December 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $96.47, for a total transaction of $415,013.94.
• On Wednesday, November 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $86.23, for a total transaction of $370,961.46.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA traded down $6.78 during midday trading on Friday, hitting $85.30. 258,449 shares of the stock traded hands, compared to its average volume of 212,680. The firm has a market capitalization of $1.01 billion, a P/E ratio of -32.43 and a beta of -0.16. The firm has a 50-day moving average of $97.34 and a two-hundred day moving average of $69.96. Palvella Therapeutics, Inc. has a one year low of $12.10 and a one year high of $114.69.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18). Equities analysts forecast that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Craig Hallum initiated coverage on shares of Palvella Therapeutics in a report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target for the company. Mizuho assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $205.00 price objective for the company. Raymond James Financial restated a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Oppenheimer reaffirmed an “outperform” rating and set a $200.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. Finally, HC Wainwright set a $200.00 price objective on shares of Palvella Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $158.69.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PVLA. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics in the 3rd quarter worth $28,000. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the third quarter valued at approximately $36,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Palvella Therapeutics in the second quarter worth approximately $37,000. JPMorgan Chase & Co. raised its position in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Palvella Therapeutics during the 2nd quarter worth $85,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.